The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study

被引:143
作者
Velloza, Jennifer [1 ]
Khoza, Nomhle [2 ]
Scorgie, Fiona [2 ]
Chitukuta, Miria [3 ]
Mutero, Prisca [3 ]
Mutiti, Kudzai [3 ]
Mangxilana, Nomvuyo [4 ]
Nobula, Lumka [4 ]
Bulterys, Michelle A. [1 ]
Atujuna, Millicent [4 ]
Hosek, Sybil [5 ]
Heffron, Renee [1 ]
Bekker, Linda-Gail [6 ]
Mgodi, Nyaradzo [3 ]
Chirenje, Mike [3 ]
Celum, Connie [1 ]
Delany-Moretlwe, Sinead [7 ]
机构
[1] Univ Washington, Seattle, WA 98195 USA
[2] Wits Reprod Hlth & HIV Inst Wits RHI, Johannesburg, South Africa
[3] Univ Zimbabwe, Coll Hlth Sci, Clin Trials Res Ctr, Harare, Zimbabwe
[4] Desmond Tutu HIV Fdn, Cape Town, South Africa
[5] Stroger H Hosp Cook Cty, Chicago, IL USA
[6] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Cape Town, South Africa
[7] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa
关键词
Stigma; disclosure; HIV; pre-exposure prophylaxis; Africa; women; PREEXPOSURE PROPHYLAXIS; MEN; TRIAL; INFORMATION; PREVENTION; INFECTION; SERVICES; SEX;
D O I
10.1002/jia2.25463
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Stigma and disclosure concerns have been key barriers to oral pre-exposure prophylaxis (PrEP) adherence for African adolescent girls and young women (AGYW) in efficacy trials. We aimed to understand the impact of these factors among African AGYW in an open-label PrEP study. Methods HPTN 082 was an open-label PrEP study among AGYW (ages 16 to 24) in Harare, Zimbabwe, and Cape Town and Johannesburg, South Africa from 2016 to 2018. Women starting PrEP were randomized to standard adherence support (counselling, two-way SMS, monthly adherence clubs) or standard support plus drug-level feedback. Serial in-depth interviews were conducted among 67 AGYW after 13-week and 26-week study visits to explore experiences of stigma, disclosure and PrEP adherence. We analysed data by coding transcripts and memo-writing and diagramming to summarize themes. Results AGYW described stigma related to sexual activity (e.g. "people say I'm a prostitute") and being perceived to be living with HIV because of taking antiretrovirals (e.g. "my husband's friends say I'm HIV infected"). Participants who anticipated stigma were reluctant to disclose PrEP use and reported adherence challenges. Disclosure also resulted in stigmatizing experiences. Across all sites, negative descriptions of stigma and disclosure challenges were more common in the first interview. In the second interview, participants often described disclosure as an "empowering" way to combat community-level PrEP stigma; many said that they proactively discussed PrEP in their communities (e.g. became a "community PrEP ambassador"), which improved their ability to take PrEP and encourage others to use PrEP. These empowering disclosure experiences were facilitated by ongoing HPTN 082 study activities (e.g. counselling sessions, adherence clubs) in which they could discuss PrEP-related stigma, disclosure and PrEP adherence issues. Conclusions Stigma and disclosure challenges were initial concerns for African AGYW newly initiating PrEP but many were empowered to disclose PrEP use over their first six months of PrEP use, which helped them cope with stigma and feel more able to take PrEP regularly. PrEP programmes can foster disclosure through community and clinic-based discussion, adherence clubs and activities normalizing sexual behaviour and PrEP use, which can reduce stigma and improve PrEP adherence and thus effectiveness.
引用
收藏
页数:10
相关论文
共 61 条
  • [1] Global PrEP roll-out: recommendations for programmatic success
    Amico, K. Rivet
    Bekker, Linda-Gail
    [J]. LANCET HIV, 2019, 6 (02): : E137 - E140
  • [2] Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework
    Amico, K. Rivet
    Wallace, Melissa
    Bekker, Linda-Gail
    Roux, Surita
    Atujuna, Millicent
    Sebastian, Elaine
    Dye, Bonnie J.
    Elharrar, Vanessa
    Grant, Robert M.
    [J]. AIDS AND BEHAVIOR, 2017, 21 (05) : 1361 - 1375
  • [3] Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy
    Anderson, Peter L.
    Liu, Albert Y.
    Castillo-Mancilla, Jose R.
    Gardner, Edward M.
    Seifert, Sharon M.
    McHugh, Cricket
    Wagner, Theresa
    Campbell, Kayla
    Morrow, Mary
    Ibrahim, Mustafa
    Buchbinder, Susan
    Bushman, Lane R.
    Kiser, Jennifer J.
    MaWhinney, Samantha
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (01)
  • [4] [Anonymous], 2018, ORAL PRESENTATION C
  • [5] Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study
    Atujuna, Millicent
    Newman, Peter A.
    Wallace, Melissa
    Eluhu, Megan
    Rubincam, Clara
    Brown, Ben
    Bekker, Linda-Gail
    [J]. PLOS ONE, 2018, 13 (02):
  • [6] Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
    Baeten, J. M.
    Donnell, D.
    Ndase, P.
    Mugo, N. R.
    Campbell, J. D.
    Wangisi, J.
    Tappero, J. W.
    Bukusi, E. A.
    Cohen, C. R.
    Katabira, E.
    Ronald, A.
    Tumwesigye, E.
    Were, E.
    Fife, K. H.
    Kiarie, J.
    Farquhar, C.
    John-Stewart, G.
    Kakia, A.
    Odoyo, J.
    Mucunguzi, A.
    Nakku-Joloba, E.
    Twesigye, R.
    Ngure, K.
    Apaka, C.
    Tamooh, H.
    Gabona, F.
    Mujugira, A.
    Panteleeff, D.
    Thomas, K. K.
    Kidoguchi, L.
    Krows, M.
    Revall, J.
    Morrison, S.
    Haugen, H.
    Emmanuel-Ogier, M.
    Ondrejcek, L.
    Coombs, R. W.
    Frenkel, L.
    Hendrix, C.
    Bumpus, N. N.
    Bangsberg, D.
    Haberer, J. E.
    Stevens, W. S.
    Lingappa, J. R.
    Celum, C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (05) : 399 - 410
  • [7] Balkus JE, 2016, JAIDS-J ACQ IMM DEF, V72, P333, DOI 10.1097/QAI.0000000000000974
  • [8] Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial
    Bekker, Linda-Gail
    Roux, Surita
    Sebastien, Elaine
    Yola, Ntando
    Amico, K. Rivet
    Hughes, James P.
    Marzinke, Mark A.
    Hendrix, Craig W.
    Anderson, Peter L.
    Elharrar, Vanessa
    Stirratt, Michael
    Rooney, James F.
    Piwowar-Manning, Estelle
    Eshleman, Susan H.
    McKinstry, Laura
    Li, Maoji
    Dye, Bonnie J.
    Grant, Robert M.
    [J]. LANCET HIV, 2018, 5 (02): : E68 - E78
  • [9] Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection
    Bekker, Linda-Gail
    Rebe, Kevin
    Venter, Francois
    Maartens, Gary
    Moorhouse, Michelle
    Conradie, Francesca
    Wallis, Carole
    Black, Vivian
    Harley, Beth
    Eakles, Robyn
    [J]. SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, 2016, 17 (01)
  • [10] A Mobile-Based App (MyChoices) to Increase Uptake of HIV Testing and Pre-Exposure Prophylaxis by Young Men Who Have Sex With Men: Protocol for a Pilot Randomized Controlled Trial
    Biello, Katie B.
    Marrow, Elliot
    Mimiaga, Matthew J.
    Sullivan, Patrick
    Hightow-Weidman, Lisa
    Mayer, Kenneth H.
    [J]. JMIR RESEARCH PROTOCOLS, 2019, 8 (01):